The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis-Reference-Cited by-同舟云学术

The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis

Published:2015-10-12 Issue:11 Volume:47 Page:1346-1351
ISSN:1061-4036
Container-title:Nature Genetics
language:en
Short-container-title:Nat Genet

Author:

Pomerantz Mark M,Li Fugen,Takeda David Y,Lenci Romina,Chonkar Apurva,Chabot Matthew,Cejas Paloma,Vazquez Francisca,Cook Jennifer,Shivdasani Ramesh A^ORCID,Bowden Michaela,Lis Rosina,Hahn William C,Kantoff Philip W,Brown Myles,Loda Massimo,Long Henry W,Freedman Matthew L

Publisher

Springer Science and Business Media LLC

Subject

Genetics

Link

http://www.nature.com/articles/ng.3419.pdf

Reference36 articles.

1. Whyte, W.A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307–319 (2013).

2. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 (2012).

3. Lupien, M. & Brown, M. Cistromics of hormone-dependent cancer. Endocr. Relat. Cancer 16, 381–389 (2009).

4. Thompson, I.M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215–224 (2003).

5. Huggins, C. Endocrine-induced regression of cancers. Cancer Res. 27, 1925–1930 (1967).

Cited by 352 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy;Cancer Letters;2024-10

2. Epigenotoxicity: Decoding the epigenetic imprints of genotoxic agents and their implications for regulatory genetic toxicology;Environmental and Molecular Mutagenesis;2024-09-12

3. NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis;Nature Genetics;2024-09-09

4. Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers;Nature Cancer;2024-09-06

5. MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer;Cancer Research Communications;2024-09-01